Last reviewed · How we verify
Eschscholzia tablets
Eschscholzia tablets is a Herbal extract / Natural anxiolytic Small molecule drug developed by A. Vogel AG. It is currently in Phase 3 development for Anxiety and nervous tension, Sleep disturbances and insomnia support.
Eschscholzia californica (California poppy) extract acts as a mild sedative and anxiolytic agent, likely through modulation of GABAergic and other neurotransmitter systems.
Eschscholzia californica (California poppy) extract acts as a mild sedative and anxiolytic agent, likely through modulation of GABAergic and other neurotransmitter systems. Used for Anxiety and nervous tension, Sleep disturbances and insomnia support.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Eschscholzia tablets |
|---|---|
| Sponsor | A. Vogel AG |
| Drug class | Herbal extract / Natural anxiolytic |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Sleep Medicine / Neurology |
| Phase | Phase 3 |
Mechanism of action
The plant contains alkaloids such as californine and other compounds that may enhance GABAergic neurotransmission and promote relaxation. These constituents are believed to reduce nervous tension and support natural sleep patterns without the potency of synthetic sedatives. The exact molecular mechanisms remain incompletely characterized but are consistent with traditional herbal use for anxiety and sleep support.
Approved indications
- Anxiety and nervous tension
- Sleep disturbances and insomnia support
Common side effects
- Drowsiness
- Dizziness
- Headache
- Gastrointestinal upset
Key clinical trials
- Eschscholzia Study (PHASE3)
- Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eschscholzia tablets CI brief — competitive landscape report
- Eschscholzia tablets updates RSS · CI watch RSS
- A. Vogel AG portfolio CI
Frequently asked questions about Eschscholzia tablets
What is Eschscholzia tablets?
How does Eschscholzia tablets work?
What is Eschscholzia tablets used for?
Who makes Eschscholzia tablets?
What drug class is Eschscholzia tablets in?
What development phase is Eschscholzia tablets in?
What are the side effects of Eschscholzia tablets?
Related
- Drug class: All Herbal extract / Natural anxiolytic drugs
- Manufacturer: A. Vogel AG — full pipeline
- Therapeutic area: All drugs in Psychiatry / Sleep Medicine / Neurology
- Indication: Drugs for Anxiety and nervous tension
- Indication: Drugs for Sleep disturbances and insomnia support
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing